Cybin to participate at the 26th annual milken institute global conference

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that doug drysdale, cybin's chief executive officer, will be speaking at the 26th annual milken institute global conference on a panel entitled “progress and innovation: the dawning of a new day in treating mental health.” the.
CYBN Ratings Summary
CYBN Quant Ranking